[(1-Ethyl-1H-pyrazol-4-yl)methyl]triphenylphosphonium chloride hydrochloride | 675149-26-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: [(1-Ethyl-1H-pyrazol-4-yl)methyl]triphenylphosphonium chloride hydrochloride
• 英文别名: (1-ethylpyrazol-4-yl)methyl-triphenylphosphanium;chloride;hydrochloride
• CAS: 675149-26-5
• 化学式: C₂₄H₂₄N₂P*ClH*Cl
• 分子量: 443.356
• InChiKey: ZAXHYIMETPJVBN-UHFFFAOYSA-M

计算性质

• 辛醇/水分配系数(LogP)：
  1.82
• 重原子数：
  29
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  17.8
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  [(1-Ethyl-1H-pyrazol-4-yl)methyl]triphenylphosphonium chloride hydrochloride 、 2-(tert-Butyldiphenylsilyloxymethyl)-1-phenylcyclopropanecarbaldehyde 在 potassium tert-butylate 作用下， 以 四氢呋喃 、 二甲基亚砜 为溶剂， 反应 3.25h， 生成 4-{(E,Z)-2-[2-(tert-butyldiphenylsilyloxymethyl)-1-phenylcyclopropyl]vinyl}-1-ethyl-1H-pyrazole
  参考文献：
  名称：

  CYCLOPROPANE DERIVATIVES

  摘要：

  由以下公式（I）表示的环丙烷衍生物或其药用可接受的盐具有促进促进醒脑肽受体的作用，因此，极其有用作为预防或治疗由促进醒脑肽引起的睡眠障碍或失眠症的药物，包括失眠作为典型例子：其中A1、A2和A3各自独立地表示芳基、杂环烷基或类似物，R1、R2和R3各自独立地表示氢原子、C1-6烷基或类似物，X表示氧原子或类似物，L表示键或类似物。

  公开号：

  US20120165339A1
• 作为产物：
  描述：

  4-(chloromethyl )-1-ethyl-1H-pyrazole hydrochloride 、 三苯基膦 以 乙腈 为溶剂， 反应 20.0h， 以to obtain the title compound (5.73 g)的产率得到[(1-Ethyl-1H-pyrazol-4-yl)methyl]triphenylphosphonium chloride hydrochloride
  参考文献：
  名称：

  CYCLOPROPANE DERIVATIVES

  摘要：

  下列式子(I)所代表的环丙烷衍生物或其药学上可接受的盐，具有促进睡眠的荷尔蒙受体抑制作用，因此，极其有用于预防或治疗因荷尔蒙受体引起的睡眠障碍或失眠症，包括典型的失眠症：其中A1、A2和A3各自独立地代表芳基、杂环基或类似物，R1、R2和R3各自独立地代表氢原子、C1-6烷基或类似物，X代表氧原子或类似物，L代表键或类似物。

  公开号：

  US20120165339A1

文献信息

• FIVE-MEMBERED HETEROCYCLIC COMPOUNDS
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP1541564A1

  公开（公告）日：2005-06-15

  The present invention provides a compound represented by the formula: wherein R1 is an optionally substituted 5-membered heterocyclic group; X, Y and V are the same or different and each is a bond, an oxygen atom, a sulfur atom and the like; Q is a divalent hydrocarbon group having 1 to 20 carbon atoms; ring A is an aromatic ring optionally further having 1 to 3 substituents; Z is -(CH2)n-Z1- or -Z1-(CH2)n- (n is an integer of 0 to 8, Z1 is a bond, an oxygen atom, a sulfur atom and the like); ring B is a nitrogen-containing heterocycle optionally further having 1 to 3 substituents; W is a bond or a divalent hydrocarbon group having 1 to 20 carbon atoms; R2 is a hydrogen atom, a cyano group, -PO(OR9)(OR10) (R9 and R10 are the same or different and each is a hydrogen atom or an optionally substituted hydrocarbon group, and R9 and R10 are optionally bonded to form an optionally substituted ring) and the like, or a salt thereof, which has a superior adipose tissue weight decreasing action, a hypoglycemic action and a hypolipidemic action, and which is useful as an agent for the prophylaxis or treatment of obesity, diabetes mellitus, hyperlipidemia, impaired glucose tolerance, hypertension and the like.

  本发明提供了一种由以下式表示的化合物： 其中R1是可选择地取代的5-成员杂环基团；X、Y和V相同或不同，每个都是键，氧原子，硫原子等；Q是具有1到20个碳原子的二价碳氢基团；环A是一个芳香环，可选择地进一步具有1到3个取代基；Z是-(CH2)n-Z1-或-Z1-(CH2)n-（n是0到8的整数，Z1是键，氧原子，硫原子等）；环B是一个含氮杂环，可选择地进一步具有1到3个取代基；W是键或具有1到20个碳原子的二价碳氢基团；R2是氢原子，氰基，-PO(OR9)(OR10)（R9和R10相同或不同，每个是氢原子或可选择地取代的碳氢基团，R9和R10可选择地结合形成可选择地取代的环）等，或其盐，具有优越的减少脂肪组织重量的作用，降糖作用和降脂作用，并且作为预防或治疗肥胖症，糖尿病，高脂血症，糖耐量受损，高血压等的药剂是有用的。
• Five-membered heterocyclic compounds
  申请人：Momose Yu

  公开号：US20060135578A1

  公开（公告）日：2006-06-22

  The present invention provides a compound represented by the formula: wherein R 1 is an optionally substituted 5-membered heterocyclic group; X, Y and V are the same or different and each is a bond, an oxygen atom, a sulfur atom and the like; Q is a divalent hydrocarbon group having 1 to 20 carbon atoms; ring A is an aromatic ring optionally further having 1 to 3 substituents; Z is —(CH 2 ) n -Z 1 - or -Z 1 -(CH 2 ) n — (n is an integer of 0 to 8, Z 1 is a bond, an oxygen atom, a sulfur atom and the like); ring B is a nitrogen-containing heterocycle optionally further having 1 to 3 substituents; W is a bond or a divalent hydrocarbon group having 1 to 20 carbon atoms; R 2 is a hydrogen atom, a cyano group, —PO(OR 9 )(OR 10 ) (R 9 and R 10 are the same or different and each is a hydrogen atom or an optionally substituted hydrocarbon group, and R 9 and R 10 are optionally bonded to form an optionally substituted ring) and the like, or a salt thereof, which has a superior adipose tissue weight decreasing action, a hypoglycemic action and a hypolipidemic action, and which is useful as an agent for the prophylaxis or treatment of obesity, diabetes mellitus, hyperlipidemia, impaired glucose tolerance, hypertension and the like.

  本发明提供一种化合物，其化学式表示为：其中，R1为可选取的取代的5-成员杂环基；X、Y和V相同或不同，每个都是键，氧原子，硫原子等；Q为具有1到20个碳原子的二价碳氢基团；环A为芳香环，可选地进一步具有1到3个取代基；Z为—(CH2)n-Z1-或-Z1-(CH2)n—（n为0到8的整数，Z1为键，氧原子，硫原子等）；环B为含氮杂环，可选地进一步具有1到3个取代基；W为键或具有1到20个碳原子的二价碳氢基团；R2为氢原子，氰基，—PO(OR9)(OR10)（R9和R10相同或不同，每个都是氢原子或可选取的取代的碳氢基团，R9和R10可选择性地结合形成可选取的取代环）等，或其盐，具有优异的减轻脂肪组织重量、降血糖和降血脂作用，可用作预防或治疗肥胖症、糖尿病、高脂血症、糖耐量受损、高血压等的药剂。
• US7368578B2
  申请人：——

  公开号：US7368578B2

  公开（公告）日：2008-05-06
• CYCLOPROPANE DERIVATIVES
  申请人：Terauchi Taro

  公开号：US20120165339A1

  公开（公告）日：2012-06-28

  A cyclopropane derivative represented by the following formula (I) or a pharmaceutically acceptable salt thereof has orexin receptor inhibitory action, and thus, is extremely useful as an agent for preventing or treating sleep disorder or dyssomnia caused by orexin, including insomnia as a typical example: wherein A 1 , A 2 and A 3 each independently represent an aryl group, a heterocyclyl group or the like, R 1 , R 2 and R 3 each independently represent a hydrogen atom, a C 1-6 alkyl group or the like, X represents an oxygen atom or the like, and L represents a bond or the like.

  由以下公式（I）表示的环丙烷衍生物或其药用可接受的盐具有促进促进醒脑肽受体的作用，因此，极其有用作为预防或治疗由促进醒脑肽引起的睡眠障碍或失眠症的药物，包括失眠作为典型例子：其中A1、A2和A3各自独立地表示芳基、杂环烷基或类似物，R1、R2和R3各自独立地表示氢原子、C1-6烷基或类似物，X表示氧原子或类似物，L表示键或类似物。